



Protocol for Human P450 Metabolite Identification & Production

PROCEDURAL NOTES

- Unlike older *in vitro* P450 systems, *CypExpress*TM does NOT require addition of glucose 6-phosphate dehydrogenase (G6PDH) or magnesium for activity. In fact, certain metals, such as magnesium and calcium may complex with some substrates – thereby reducing solubility and metabolite production.
- Substrate concentrations up to 3.0 mM have been used with *CypExpress*TM. Typically we use 50-200 µM for P450 profiling and metabolite identification or 500 µM-1 mM for scale-up metabolite synthesis. The concentration that produces the highest concentration of metabolites varies for each compound and can be optimized using the Pilot Procedure (see below).
- Small-volume reactions can be performed in 24-well microplates provided that there is sufficient agitation for optimal aeration.
- Many drugs are poorly water-soluble and will be difficult to dissolve in buffer. This can be remedied by preparing a concentrated solution of the drug in dimethylsulfoxide or *N,N*-dimethylformamide and adding it to the buffer. DMSO & DMF are the preferred solvents, with a final concentration (v/v) preferably 2% or less in the final reaction mixture. Methanol (0.5-1.0% v/v) may be used, but even at low concentrations may strongly inhibit the activity of some P450 isoforms.
- A 100 mg/mL concentration of *CypExpress*TM is typically best for P450 profiling and metabolite identification. The concentration of *CypExpress*TM for Scale-up metabolite synthesis can be lowered for good substrates, especially when employing the Multi-Cycle Procedure.



Materials

- *CypExpress*TM powder
- 100 mM, pH 7.4 potassium phosphate buffer containing:
 - 5.0 mM glucose-6-phosphate (G6P)
 - 2.0 mM nicotinamide adenine dinucleotide phosphate, sodium salt (NADP⁺)
 - Substrate concentration of 500 μ M to 3.0 mM
- Pilot Procedure for Scale-up synthesis:
 - Glass test tubes or flasks with Teflon stir bars
- For P450 Profiling and Metabolite Identification
 - 24 or 48 well microplate and microplate shaker

Pilot Procedure

– Use this method to evaluate reaction conditions and optimize metabolite production –

1. Allow all reagents to come to room temperature.
2. Place the *CypExpress*TM powder into a test tube with a stir bar. A 16 mm by 125 mm tube works well.
3. Add 1.0 mL of buffer containing substrate, G6P and NADP⁺ to the powder and vortex to make a suspension. Use a glass rod or pipette tip to break-up small pieces and lumps.
4. Stir the uncovered tube at 37°C at a rate fast enough to create a vortex.
5. Allow the reaction to proceed for four hours.
6. Quench the reaction with 1.0 mL of HPLC solvent (e.g. methanol or acetonitrile), and centrifuge it at 6,000 \times *g* for 10 minutes at room temperature.
7. Remove the supernatant and proceed with metabolite separation and analysis.



Multi-Cycle and Scale-Up Procedure

– Use this method to produce larger quantities of metabolites –

1. Scale-up the Pilot Procedure by multiplying the *CypExpress*TM powder amount and buffer volume by the same factor.
 - For example, 10 g of *CypExpress*TM powder and 100 mL of buffer containing NADP⁺, G6P and 1.0 mM substrate in a 250 mL flask.
2. Allow all reagents to come to room temperature.
3. Place the *CypExpress*TM powder into the flask containing the stir bar.
4. Add the buffer containing substrate, G6P and NADP⁺ to the powder and shake to make a suspension. Use a glass rod or spatula to break-up small pieces and lumps.
5. Stir the uncovered flask at 37°C at a rate fast enough to create a vortex.
6. Allow the reaction to proceed for four hours.
7. Centrifuge the suspension at 6,000 × *g* for 10 minutes at room temperature.
8. Remove the supernatant containing the metabolites.
9. If metabolite production was low, another cycle may be performed by resuspending the pellet in fresh buffer containing NADP⁺, G6P and substrate.
10. Repeat steps 4 thru 8 up to three times.
11. Before the final centrifugation, add an equal volume of solvent (e.g. methanol or acetone) to the reaction mixture to extract any metabolites that may have been absorbed into the *CypExpress*TM powder.
12. Combine all supernatant fractions for metabolite separation and isolation.

If you have any questions, please contact us:

Toll free: 800.692.4633

Fax: 248.852.4466

email: info@oxfordbiomed.com

www.oxfordbiomed.com

Warranty and Limitation of Remedy

Oxford Biomedical Research, Inc. (OBR) makes no warranty or guarantee of any kind, whether written, oral, expressed or implied that includes without limitation, any warranty of fitness for a particular purpose, suitability and merchantability which extends beyond the description of the reagents/chemicals here. OBR warrants only to the original purchaser that the materials in this kit will meet product specifications at the time of delivery. OBR will complete its delivery obligations with care and handling. Under no circumstances will OBR have any obligation or liability, whether in tort (including negligence) or in contract, for any direct, indirect, consequential or incidental damages, even if OBR is informed about the possibility of their existence. This limitation of liability does not apply in the case of intentional acts or negligence of OBR or its employees.

The Buyer's exclusive remedy and OBR's sole liability shall be limited to a refund of the purchase price of the kit, or at the discretion of OBR, the replacement of the kit at no cost to the buyer, of all material that fails to meet our specifications. Said refund or replacement is conditional on the Buyer giving written notice to OBR within thirty (30) days of receipt of the material. Failure of Purchaser to give said notice within thirty (30) days shall constitute a waiver by Purchaser of all claims hereunder with respect to said material.

